Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer

V H de Almeida1,2, A C de Melo1, D D Meira3

  • 1Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brasil.

Insights

Radiotherapy can increase expression of p53, ERCC1, and EGFR in cervical cancer tissues, but not cell lines. This suggests a potential radioresistance mechanism in patients, differing from in vitro models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy Research

Background:

  • Cervical cancer remains a significant public health concern.
  • The molecular basis of radioresistance in cervical cancer is not fully understood.

Purpose of the Study:

  • To investigate the modulation of key molecules (EGFR, ERCC1, p53) in response to radiotherapy in cervical cancer.
  • To compare the in vitro response of cancer cell lines with the in vivo response of patient tissues.

Main Methods:

  • Quantitative PCR and Western blotting for EGFR, ERCC1, and p53 expression in CASKI and C33A cell lines.
  • Immunohistochemistry for EGFR, ERCC1, and p53 in patient tissues before and after radiotherapy.
  • TP53 gene mutation analysis by direct sequencing.

Main Results:

  • Cell lines showed minimal modulation of EGFR, ERCC1, and p53 after 1.8 Gy irradiation.
  • Malignant tissues from patients exhibited increased expression of p53 (P=0.0239) and ERCC1 (P=0.0294) post-radiotherapy.
  • EGFR expression also increased in patient tissues (P=0.1773), though less significantly. TP53 mutations were rare.

Conclusions:

  • A single radiotherapy dose induces EGFR, ERCC1, and p53 expression in patient tissues, unlike cancer cell lines.
  • This highlights a discrepancy between in vitro and in vivo models for cervical cancer radioresistance.
  • Further studies with larger patient cohorts are needed to confirm if this upregulation contributes to radioresistance.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K